<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784951</url>
  </required_header>
  <id_info>
    <org_study_id>2016/304/REK vest</org_study_id>
    <nct_id>NCT02784951</nct_id>
  </id_info>
  <brief_title>Use of Blood and Plasma in Norwegian Physician-staffed Helicopter Emergency Medical Systems</brief_title>
  <acronym>ProHEMS</acronym>
  <official_title>Use of Blood and Plasma in Prehospital Haemorrhagic Shock - a Prospective, Multicenter, Observational Trial of Advanced Deployment of Blood Products in Norwegian Physician-staffed Helicopter Emergency Medical Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sykehuset Innlandet HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Førde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the use of RBC, FDP, WB in the treatment of
      exsanguinating patients by physician-staffed emergency medical services in Norway, with focus
      on prehospital transfusion complications and safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates prehospital transfusion therapy in exsanguinating patients treated by
      physician-staffed emergency medical services in Norway, with the following main questions:

      I. Are out-of-hospital transfusions associated with an increase in adverse transfusion events
      compared to inhospital transfusions?

      II. Is out-of-hospital physician administration of plasma or blood products in exsanguinating
      patients feasible?

      III. Are patients in need of blood product transfusion possible to identify and transfuse in
      the prehospital phase/environment?

      IV. Are out-of-hospital transfusion practices associated with increased waste of blood
      products?

      All patients in haemorrhagic shock needing volume replacement and receiving prehospital
      transfusion of blood products will be included, if they fulfill the listed criteria below:

        -  Patients with mechanism of injury compatible with severe haemorrhage and/or haemorrhagic
           shock (e.g. penetrating torso injury, visible massive bleeding)

        -  Radial pulse &gt; 100 beats/min or absent/weak radial pulse

        -  Systolic blood pressure (SBP) &lt; 90 mmHg

        -  Altered mental status (reduced GCS) in the absence of head injury or known intoxication

      Patients with known previous serious allergic reactions to blood product transfusions or
      patients who refuse blood products on religious grounds (e.g. Jehovah´s Witness) will be
      excluded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>adverse transfusion reactions</measure>
    <time_frame>24 hours</time_frame>
    <description>Fraction of patients with suspected adverse transfusion reactions after administration of plasma and/or blood products.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>patients included</measure>
    <time_frame>24 hours</time_frame>
    <description>Fraction of patients fulfilling inclusion criteria with prehospital administration of blood products</description>
  </primary_outcome>
  <primary_outcome>
    <measure>units not used</measure>
    <time_frame>24 hours</time_frame>
    <description>Fraction of prepared plasma or blood units not used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of adverse events (e.g. transfusion related complications or reactions (first 24 hrs))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of adverse events</measure>
    <time_frame>24 hours</time_frame>
    <description>Type of adverse events (e.g. transfusion related complications or reactions (first 24 hrs))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of transfusion</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of transfusions given prehospital and inhospital (first 24 hrs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of transfusion</measure>
    <time_frame>24 hours</time_frame>
    <description>type of transfusions given prehospital and inhospital (first 24 hrs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure (SBP)</measure>
    <time_frame>24 hours</time_frame>
    <description>Systolic blood pressure (SBP) on scene and at admission hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate (HR)</measure>
    <time_frame>24 hours</time_frame>
    <description>heart rate (HR) on scene and at admission hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow Coma Score (GCS)</measure>
    <time_frame>24 hours</time_frame>
    <description>Glasgow Coma Score (GCS) on scene and at admission hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate (RR)</measure>
    <time_frame>24 hours</time_frame>
    <description>Respiratory rate (RR) on scene and at admission hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse oximeter (SPO2)</measure>
    <time_frame>24 hours</time_frame>
    <description>Pulse oximeter (SPO2) on scene and at admission hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response time (minutes)</measure>
    <time_frame>24 hours</time_frame>
    <description>Physician staffed emergency medical services response (in minutes) from dispatch to arrival on-scene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>on-scene time (minutes)</measure>
    <time_frame>24 hours</time_frame>
    <description>Time (in minutes) from emergency medical services arrival on-scene until patients leaves the scene or is pronounced dead on-scene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transport time (minutes)</measure>
    <time_frame>24 hours</time_frame>
    <description>Time (in minutes) from the patients leaves the scene until patient arrives in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of surgical interventions</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of surgical interventions (first 24 hrs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of surgical interventions</measure>
    <time_frame>24 hours</time_frame>
    <description>type of surgical interventions (first 24 hrs)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hemorrhagic Shock</condition>
  <arm_group>
    <arm_group_label>Single group</arm_group_label>
    <description>Patients in haemorrhagic shock needing volume replacement and receiving prehospital transfusion of blood products, either red blood cells (RBC), freeze dried plasma (FDP) or whole blood (WB).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Red blood cells (0Rh D-neg)</intervention_name>
    <description>Fresh produced RBC</description>
    <arm_group_label>Single group</arm_group_label>
    <other_name>RBC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Whole blood (O Rh D-neg K-neg)</intervention_name>
    <description>Fresh produced WB</description>
    <arm_group_label>Single group</arm_group_label>
    <other_name>WB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Freeze dried plasma (LyoPlas)</intervention_name>
    <description>(LyoPlas N-w (German Red Cross)</description>
    <arm_group_label>Single group</arm_group_label>
    <other_name>FDP</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients (pediatric and adult) in haemorrhagic shock needing volume replacement and
        receiving prehospital transfusion of blood products by treating physician staffed emergency
        medical services.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients in haemorrhagic shock needing volume replacement and receiving
             prehospital transfusion of blood products according to listed indicators below:

               -  Patients with mechanism of injury compatible with severe haemorrhage and/or
                  haemorrhagic shock (e.g. penetrating torso injury, visible massive bleeding)

               -  Radial pulse &gt; 100 beats/min or absent/weak radial pulse

               -  Systolic blood pressure (SBP) &lt; 90 mmHg

               -  Altered mental status (reduced GCS) in the absence of head injury or known
                  intoxication

        Exclusion Criteria:

          -  Patients with known previous serious allergic reactions to blood product transfusions

          -  Patients who refuse blood products on religious grounds, e.g. Jehovah´s Witness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanne Klausen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Director, Kirurgisk Serviceklinikk, Haukeland Universitetssykehus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geir A Sunde, MD</last_name>
    <phone>+47 99204008</phone>
    <email>gasu@helse-bergen.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jon-Kenneth Heltne, MD, PhD</last_name>
    <email>jkhe@helse-bergen.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sørlandet Hospital HF</name>
      <address>
        <city>Arendal</city>
        <zip>4809</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Jacobsen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rannveig Andersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geir A Sunde, MD</last_name>
      <phone>+47 99204008</phone>
      <email>gasu@helse-bergen.no</email>
    </contact>
    <contact_backup>
      <last_name>Jon-Kenneth Heltne, MD, PhD</last_name>
      <email>jkhe@helse-bergen.no</email>
    </contact_backup>
    <investigator>
      <last_name>Geir A Sunde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innlandet Hospital Trust</name>
      <address>
        <city>Brumunddal</city>
        <zip>2380</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Simensen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Simensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vestre Viken Hospital Trust</name>
      <address>
        <city>Drammen</city>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann-Elin Tomlinson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ann-Elin Tomlinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Førde</name>
      <address>
        <city>Førde</city>
        <zip>6807</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svein O Vingsnes, MD</last_name>
    </contact>
    <investigator>
      <last_name>Svein O Vingsnes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halvard Stave, MD</last_name>
    </contact>
    <investigator>
      <last_name>Halvard Stave, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Stavanger HF</name>
      <address>
        <city>Stavanger</city>
        <zip>8100</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Håkon B Abrahamsen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Håkon B Abrahamsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knut Fredriksen, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Knut Fredriksen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Olav University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Kruger, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Eivinn Å Skjærseth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Shock, Hemorrhagic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

